Article Text

PDF

P18 Liver fibrosis assessed by transient elastography predicts response in chronic hepatitis C infected patients treated with PEG-Interferon and Ribavirin
  1. A N S Nkhoma,
  2. D A Sheridan,
  3. D A Price,
  4. M L Schmid,
  5. C Miller,
  6. K Baxter,
  7. M F Bassendine,
  8. S McPherson
  1. Freeman Hospital, Joint Viral Hepatitis Clinic

Abstract

Introduction Chronic hepatitis C virus infection (HCV) is a common cause of cirrhosis and end stage liver disease. Treatment with Pegylated interferon (PEG-IFN) and ribavirin (RBV) results in sustained virological response (SVR) in approximately 60% of infected individuals. Increasing stage of fibrosis is known to be a key factor associated with non-response to treatment with PEG-IFN+RBV. Traditionally, fibrosis stage has been determined by liver biopsy, but this is invasive. Newer non-invasive methods of assessing fibrosis such as transient elastography (TE) are now available.

Aim To assess baseline liver stiffness measurement (LSM) assessed by TE as a predictor of SVR in HCV-infected subjects treated with PEG-IFN+RBV.

Method Retrospective review of outcomes of treatment in naïve patients treated with PEG-IFN+RBV for HCV between 7 January and 9 June. Post-transplant and co-infected patients were excluded. Patients who had valid LSM within 6 months of treatment were included in the TE analysis.

Results 168 patients (mean age 39±10, 70% male, 14% cirrhotic, 53% high viral load) received PEG-IFN+RBV for HCV in the study period. The overall SVR rate was 59% (50% for genotype [G] 1/4 and 70% for G2/3, p<0.001). The SVR rate was only 28% in cirrhotics (10% for G1/4 and 43% for G2/3). 87 patients had a pre-treatment TE (median LSM 6.6 KPa [3.3–73]).

LSM was significantly associated with treatment response to PEG-IFN (p=0.01), with the effect more pronounced in HCV G2/3 infection (p=0.001). The optimum cut-off to predict non-response to treatment was 11 KPa. 30 patients (16%) stopped treatment due to side-effects or non-compliance, including 1 death from pneumonitis.

Conclusion (1) LSM determined by transient elastography may be used as a non-invasive tool to predict treatment response in subjects infected with HCV.

(2) LSM >11 KPa could be used to identify patients who may have lower response rates and may benefit from longer treatment.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.